By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Compugen today reported that it had cut its fourth-quarter net loss 46 percent on lower spending, as the firm's revenues continued to be insignificant.

The Tel Aviv, Israel-based firm, which uses an in silico prediction and selection platform for discovering drug and diagnostic candidates, had revenues of $25,000 for the three-month period ended Dec. 31, compared to $11,000 for the fourth quarter of 2008.

To read the full story....

Register for Free.

Already have a GenomeWeb or 360Dx account?
Login Now.

An opinion piece in the Guardian argues that President Donald Trump is uninterested in science and that might not be a bad thing for the field.

The San Francisco Chronicle reports the Veterans Affairs Health System is studying whether genetic testing can help prescribe better depression therapies.

Stat News reports that Spark Therapeutics' Luxturna is now being used to treat a wider array of patients.

In Genome Biology this week: transcription factor use among brittle stars, single-cell RNA sequencing strategy, and more.